Lakeridge Wealth Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.07M Buy
1,728
+51
+3% +$52.1K 0.76% 26
2026
Q1
$1.54M Buy
1,677
+26
+2% +$26.4K 0.66% 36
2025
Q4
$1.77M Buy
1,651
+41
+3% +$39.2K 0.81% 29
2025
Q3
$1.23M Sell
1,610
-5
-0.3% -$3.72K 0.55% 35
2025
Q2
$1.26M Buy
1,615
+12
+0.7% +$9.32K 0.58% 32
2025
Q1
$1.32M Sell
1,603
-42
-3% -$34.9K 0.66% 30
2024
Q4
$1.27M Sell
1,645
-10
-0.6% -$8.28K 0.66% 31
2024
Q3
$1.47M Buy
1,655
+1
+0.1% +$899 0.81% 25
2024
Q2
$1.5M Sell
1,654
-90
-5% -$72K 0.9% 23
2024
Q1
$1.36M Buy
1,744
+18
+1% +$12.8K 0.88% 24
2023
Q4
$1.01M Buy
+1,726
New +$1.01M 0.73% 29

Other funds holding LLY

Lakeridge Wealth Management's LLY Position: Q2 2026 in Review

Lakeridge Wealth Management increased its Eli Lilly (LLY) stake by 3% in Q2 2026, buying an estimated $52.1K and bringing the position to 1,728 shares worth $2.07M. The position accounts for 0.76% of the portfolio, ranked #26.

Lakeridge Wealth Management first reported a position in LLY in Q4 2023 and has held it in 11 quarters since. 1,857 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Lakeridge Wealth Management held 1,728 shares of Eli Lilly worth $2.07M as of Q2 2026.
  • Lakeridge Wealth Management bought 51 Eli Lilly shares in Q2 2026, an estimated $52.1K.
  • Eli Lilly made up 0.76% of Lakeridge Wealth Management's portfolio in Q2 2026, its #26 holding.
  • Lakeridge Wealth Management first reported a position in Eli Lilly in Q4 2023 and has held it in 11 quarters since.
  • 1,857 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Lakeridge Wealth Management's 13F filing for Q2 2026, filed 14 Jul 2026.